Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by M. Hide
P047 COMPLETE RESPONSE WITH LIGELIZUMAB IN CHRONIC SPONTANEOUS URTICARIA: A COMPOSITE SCORE OF SYMPTOMS AND QUALITY-OF-LIFE
Assessing the holistic effect of a treatment in patients with chronic spontaneous urticaria (CSU) requires evaluating different patient reported outcomes (PROs). In this post-hoc analysis, we evaluated complete response in patients with CSU using a composite score of various PROs. To read this article in full you will need to make a payment ACAAI Member Login ACAAI Member, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials
Summary Background Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin‐4 and interleukin‐13. International phase II and III studies have evaluated the efficacy and safety of dupilumab in adults with moderate‐to‐severe atopic dermatitis (AD ), but the effects of dupilumab in Japanese patients have not been reported. Objectives To evaluate the efficacy and safety of dupilumab in Japanese patients with moderate‐to‐severe AD .
A case of Kaposi varicelliform eruption progressing to herpes simplex virus hepatitis in an immunocompetent patient
CPD ? A memorable patientA case of Kaposi varicelliform eruption progressing to herpes simplex virus hepatitis in an immunocompetent patientAuthorsM. Okamoto,Department of Dermatology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorS. Takahagi,Department of Dermatology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorA.
A unique clinical phenotype of a patient bearing a newly identified deletion mutation in the PSENEN gene along with the pathogenic serum desmoglein-1 antibody - Kan - 2018 - Clinical and Experimental Dermatology - Wiley Online Library
CorrespondenceA unique clinical phenotype of a patient bearing a newly identified deletion mutation in the PSENEN gene along with the pathogenic serum desmoglein-1 antibodyAuthorsT. Kan,Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorS. Takahagi,Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorH.
Contact urticaria syndrome with IgE antibody against a cefotiam-unique structure, evoked by nonapparent exposure to cefotiam
A 26-year-old woman presented with recurrent attacks of widespread urticaria and systemic symptoms. The patient was a nurse, and the attacks occurred only in her workplace, without an apparent trigger. A patch test to cefotiam (CTM) induced an immediate skin reaction. ELISA detected the patient's serum IgE antibody binding to CTM conjugated with human serum albumin (CTM-HSA), and her basophils released histamine in response to CTM-HSA in a histamine release assay (HRA).
Predictive phenotyping of inherited ichthyosis by next-generation DNA sequencing
Previous article in Early View: A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus Previous article in Early View: A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus Next article in Early View: Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis Next article in Early View: Pulmonary function tests,...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with M.
Contact M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack